Neuren Pharmaceuticals Share Price and Company Fundamentals
Last traded: Yesterday at 5:10 AM
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Key Metrics
PE ratio
12.83
PB ratio
5.63
Dividend yield
-
Beta
1.74
Market cap
$1.85B
Enterprise value
$1.52B
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.neurenpharma.com |
| Mailing address | 117 Camberwell Road Suite 1.01 Hawthorn East VIC 3123 Australia |
| Phone / Fax | 61 3 9092 0480 / |
Dividends
More: Neuren Pharmaceuticals Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Neuren Pharmaceuticals paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.NEU dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Neuren Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | ||
| Ms. Lauren Frazer C.A. | CFO & Company Secretary | ||
| Dr. Clive Blower BSc (Hons), Ph.D. | Chief Operations Officer | ||
| Mr. Lawrence Glass BA (Biology) | Chief Science Officer | ||
| Mr. Gerry Zhao | Chief Business Officer | ||
| Dr. Liza A. Squires M.D. | Chief Medical Officer | ||
| Mr. Daryl Dekarske | Chief Regulatory Officer |
Profitability and management effectiveness
Profit margin
68.11%
Operating margin
38.54%
Return on assets
41.13%
Return on equity
54.96%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Neuren Pharmaceuticals is 1.85B and its enterprise value is 1.52B. The enterprise value to revenue ratio of NEU is 6.95. The enterprise value to EBITDA ratio of NEU is 8.27.
The NEU's stocks Beta value is 1.74 making it 74% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Neuren Pharmaceuticals (NEU)
Neuren Pharmaceuticals (ASX:NEU) Frequently Asked Questions
1. What is Neuren Pharmaceuticals's Stock Symbol?
Neuren Pharmaceuticals trades on ASX under the ticker symbol "NEU".
2. What is Neuren Pharmaceuticals's stock price today?
One share of NEU stock can currently be purchased for approximately $14.63.
3. How can I contact Neuren Pharmaceuticals?
Neuren Pharmaceuticals's mailing address is 117 Camberwell Road Suite 1.01 Hawthorn East VIC 3123 Australia. The company can be reached via phone at 61 3 9092 0480.
4. What is Neuren Pharmaceuticals's official website?
The official website of Neuren Pharmaceuticals is https://www.neurenpharma.com.